A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies.

Phase 1: safety assessment, dose limiting toxicity 9DLT) determination, maximum tolerated dose (MTD) determination, pharmacokinetic profile evaluation. Phase 2: safety assessment at the recommended Phase 2 dose (RPTD), preliminary efficacy assessment.